Medical research has long framed racial and ethnic minority communities through a lens of deficit and distrust, but a new perspective published in The Lancet argues that this framing is both historically incomplete and scientifically self-defeating. The authors contend that the under-representation of Black and Brown people in biomedical research is not an accident of geography or apathy, but a predictable outcome of narratives that have cast these communities as problems to be managed rather than partners to be engaged.
Historians have thoroughly documented the overt bias and outright exploitation that have marked medicine's relationship with minority populations, from unethical experimentation to the everyday exclusions embedded in clinical practice. Social scientists and policy researchers have likewise built a substantial evidence base showing how both direct and structural racism damage health outcomes across systems, including the UK's National Health Service. That record is real, and the perspective does not dispute it. The problem, the authors suggest, is that this necessary reckoning has become the only story medicine tells about race and ethnicity — a story so relentlessly negative that it leaves little room for the communities themselves to be seen as sources of insight, expertise, and scientific value.
One of the most persistent symptoms of that imbalance is the label «hard to reach,» a phrase still routinely applied to minority ethnic populations during biomedical recruitment. The perspective argues that the term functions as an implicit excuse. By describing communities as difficult to access, research institutions shift responsibility away from their own recruitment practices, their historical conduct, and their failure to build durable relationships. The result is a dangerous and well-documented under-representation in medical research — a gap that matters not only for equity but for the validity of the science itself. Treatments and interventions tested in narrow populations may not perform the same way in the people who were left out of the trials.
The authors propose a reorientation rather than a simple call for more recruitment. They describe «unimagined communities» — populations whose potential contributions to research have never been seriously imagined by the institutions that study them — and «reimagined research,» a practice in which community members help shape the questions, methods, and priorities of the studies that concern them. That shift would require researchers to confront the legacy of exploitation honestly while refusing to let that legacy define the present. It would also require abandoning the vocabulary of reachability in favor of a vocabulary of partnership.
The stakes extend beyond any single trial or institution. Medical research shapes which treatments reach the clinic, which symptoms are taken seriously, and which populations are visible to the systems meant to serve them. If minority ethnic communities remain systematically absent from that process, the resulting evidence base will continue to reflect the narrow slice of the population that research has historically found easiest to enroll. The Lancet perspective positions this as a scientific problem as much as a moral one, and it argues that the fix begins with the stories researchers tell about who belongs in the laboratory, the clinic, and the study cohort.
For research institutions, the implications are practical. Building trust after documented exploitation takes time, transparency, and a willingness to share authority over research agendas. The authors suggest that the alternative — continuing to describe entire populations as hard to reach while their absence undermines the evidence base — is no longer defensible. Reimagining research, in their account, means treating communities not as recruitment targets but as co-authors of the questions that medicine needs to answer.
